CORPORATE PRESENTATION
FEBRUARY 2016
(NYSE MKT: INFU)
Exhibit 99.1


Safe Harbor Statement
2
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Certain statements contained in this presentation are forward-looking statements and are based on future
expectations, plans and prospects for the business and operations of InfuSystem Holdings, Inc. (“InfuSystem”
or “the Company”) that involve a number of risks and uncertainties.  In connection with the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors
that could cause actual results to materially differ from those indicated by these forward-looking statements.
Those factors, risks and uncertainties include, but are not limited to: potential changes in overall healthcare
reimbursement, including CMS competitive bidding; sequestration; concentration of customers; increased
focus on early detection of cancer; competitive treatments; dependency on Medicare Supplier Number;
availability of chemotherapy drugs; global financial conditions; changes and enforcement of state and federal
laws; dependency on suppliers; risks associated with acquisitions and joint ventures, including integration risks;
US Healthcare Reform; relationships with healthcare professionals and organizations; technological changes
related to infusion therapy; dependency on websites and intellectual property; dependency on key personnel;
dependency on banking relationships; risks associated with our common stock, as well as any litigation to
which the Company may be subject from time to time; and other risk factors as discussed in the Company’s
annual report on Form 10-K for the year ended December 31, 2014 and in subsequent  filings made by the
Company from time to time with the Securities and Exchange Commission (the “SEC”), which can be obtained
via the SEC’s Edgar website or by contacting the Company or the SEC.  Forward-looking statements in this
presentation are made the date hereof, and, unless required by law, the Company disclaims any duty to
supplement, update or revise such statements, whether as a result of subsequent developments, changed
expectations or otherwise.  The Company regularly posts important information to the investors section of its
website.


InfuSystem
provides infusion pumps and related products and services for
patients in the home, oncology clinics, ambulatory surgery centers, and other
health care sites.
Improving access to quality medical equipment required by clinicians
Delivering products and processes that drive down the cost of infusion care
Promoting patient care and safety, optimizing clinical outcomes
About InfuSystem
®
(NYSE MKT: INFU)
3
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST


Investment Highlights
4
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem
is a dominant provider in the at-home
oncology infusion pump market
30%+ market share
Business generates substantial annual cash flow
$16.1 M AEBITDA in 2014
$8.5 M of Free Cash Flow*
Substantial barriers to entry for potential new
market entrants
Pump fleet / Insurance contracts / EMR
12 of the last 13 quarters have been profitable
New management team took over 3 years ago
Strong gross margins, consistently above 70%
Industry leading EMR connectivity to hospitals and
clinics
Significantly Reduced Cost of Capital
$39.0
$47.2
$54.6
$58.8
$62.3
$66.5
$68.8
$0
$10
$20
$30
$40
$50
$60
$70
$80
FY2009
FY2010
FY2011
FY2012
FY2013
FY2014
TTM
9/30/15
Revenue
$10.3
$13.1
$16.0
$16.1
$17.4
$0
$2
$4
$6
$8
$10
$12
$14
$16
$18
$20
FY2011
FY2012
FY2013
FY2014
TTM 9/30/15
Adjusted EBITDA*
2014 does NOT add-back the following charges: G&A expense on IT and Pain
Management initiatives of $0.7M, a write-off of pumps $0.4M, severance of $0.2M
*See appendix for Reg G tables.  Free Cash Flow = “Adjusted EBITDA” less “Replacement Cost of 
Retired Pumps” less “Scheduled Debt Payments of Principal” less “Interest on Debt”


InfuSystem: Leading Provider of Oncology
Infusion Pumps
5
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Core Business: Leading provider to Patients, Hospitals
and Infusion Clinics in North America
InfuSystem
enables oncology patients the comforts
of at-home treatment
Permits hospitals and clinics access to INFU’s large
inventory without a capital equipment purchase,
while improving patient outcomes and driving down
healthcare costs.
INFU generates consistent recurring rental revenue
Key Differentiators / Competitive Advantages
Largest inventory & fleet of infusion pumps: ~60,000*
~340 payor
networks under contract*
~1,700 customer/facility count*
World-class ISO service centers
Significant barriers to entry for new participants
Growth Drivers
Pain Management expansion and other cancers
Innovative EMR connectivity “InfuConnect” with
hospitals and clinics
Expanded
portfolio
-
infusion
related
disposable
sales
New infusion drugs
Four Revenue Streams to Drive Cash Flows
(FY 2014)
*As of September 30, 2015
Rental: Patient-Based
(TPP)
Rental: Hospital & 
Home Care Based (DP)
Sales: Product Sales
Rental: Service and
Repair
72%
13%
12%
3%


Dominant Player in  Our Niche
6
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem
pumps permit oncology patients to
receive treatment in the comfort of their home.
24/7 on-call oncology nurses
InfuSystem is the market leader with more than
~1,700*
customer/facility
count
-
hospitals
and
oncology practice sites served in North America.
13 of the 20 top leading cancer institutions
Total home infusion market is $10 billion.
Oncology market treatable via continuous
infusion is estimated to exceed $200 million
annually.
Cancer rates growing (NIH)
In 2015 1.7M new cases of cancer in U.S.
39.6% of men & women will be diagnosed
with cancer during their lifetimes
U.S. cancer care could reach $156 billion in
2020
At-home treatment substantially drives down
healthcare costs as mandated by ACA.
Ambulatory Continuous Infusion Opportunity**
(Oncology)
*As of September 30, 2015
**Management estimates
30%
15%
25%
20%
5%
1%
4%
InfuSystem
OIS
Home Care
Ownership
Disposable
InfusAID
Other


Management Executing On
Value-Creation Strategy
7
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
New management team focused on “Value-
Creation Strategy” through series of strategic
initiatives
Four unique business models to capture
increasing share of market opportunity and
benefit
from
changing
payor
mix
Accretive acquisition to expand market share
“Land Grab”
Expanding into adjacent addressable markets
to drive growth
Investments into next generation systems and
technologies to increase customer retention
Improving product utilization to increase return
on investment
Effective cash utilization through decreased
borrowing rates
18.8%
22.3%
25.6%
24.2%
25.3%
15%
17%
19%
21%
23%
25%
27%
FY2011
FY2012
FY2013
FY2014*
TTM 9/30/15
Adjusted EBITDA Margins
2014 does NOT add-back the following charges: G&A expense on IT and Pain
Management initiatives of $0.7M, a write-off of pumps $0.4M, severance of $0.2M


Value-Creation Strategy
8
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
FOUR REVENUE STREAMS DRIVING
CASH FLOWS


Four Revenue Streams to Drive Cash Flows
9
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Patient-Based
Rental (TPP)
72% of 2014 Sales
A hospital/clinic provides
an INFU pump to a
patient to be utilized for
at-home therapy
InfuSystem
bills patients
insurance company for
payment
Hospital-Home Care
Based Rental (Direct)
13% of 2014 Sales
A hospital/clinic rents an
INFU pump on a short
term basis or clients
choose to always rent
INFU bills  hospital/
clinic a flat rental rate
Service & Repair
3% of 2014 Sales
InfuSystem
will service
and repair pumps  for
OEMs, other secondary
market infusion pump
companies, and
hospitals/clinics
Rental Revenue
88% of 2014 Sales
Product Sales
12% of 2014 Sales
InfuSystem
will refurbish
pumps for sale to
hospitals/clinics
Customer has option
to sell back pre-owned
pumps
Ability to sell new pumps
Disposables for new and
used pumps


$7.8
$5.4
$6.3
$7.8
$6.7
$0
$1
$2
$3
$4
$5
$6
$7
$8
$9
FY2011
FY2012
FY2013
FY2014
TTM as of
9/30/15
Revenue Growth  -
Rental and Sales
10
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Product Sales
$42.7
$48.2
$49.5
$52.9
$57.4
$4.1
$5.3
$6.5
$5.8
$4.8
$46.8
$53.5
$56.0
$58.7
$62.2
$20
$25
$30
$35
$40
$45
$50
$55
$60
$65
FY2011
FY2012
FY2013
FY2014
TTM as of
9/30/15
Net Collected Rental Revenue
Bad Debt
Rental Revenues
(Gross to Net Collected)


Net Collected Revenue
11
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
14.6%
12.3%
9.7%
12.4%
12.2%
14.2%
9.7%
8.7%
6.6%
7.9%
7.3%
8.6%
0%
2%
4%
6%
8%
10%
12%
14%
16%
Q412
Q113
Q213
Q313
Q413
Q114
Q214
Q314
Q414
Q115
Q215
Q315
Bad Debt as a Percent of Rental Revenue
As new healthcare laws have been enacted, the focus on
net collected revenue becomes increasingly important as
a direct result of focus on contractual insurance changes
Company's increased focus on collecting patient billings
In-Network agreements
Improved billing protocol
High diversification of providers and payors
No single healthcare provider represents more
than 7% of Patient-Based Revenue (TPP)
Patient-Based
Rental
Payor
Mix
(FY2014 Cash Collections)
30%
1%
19%
41%
9%
Medicare
Patient
Commercial
BCBS
Medicaid


Strong Customer “Stickiness” Leads to High
Revenue Predictability
12
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Strong value placed on hospital/clinic
contracts and relationships due to strong
“reorder/recurring” revenue component
InfuSystem
provides patient-based pump
rentals through ~1,700* customer/facility
count (clinics/hospitals) with ~340* payor
networks under contract
Customer count has declined through market
consolidation, with INFU on the winning side
Oncology clinics/hospitals that account for
98.7% of patient-based pump rentals in 2013
also rented a pump in 2014
Average customer tenure (weighted by
number of pump rentals in 2014) is 9.2 years
Percent of Pump Rentals by Oncology
Clinics that Reordered in 2014 vs 2013
1,400
1,600
1,800
1,500
1,700
230
245
260
270
340
0
400
800
1,200
1,600
2,000
2,400
FY2011
FY2012
FY2013
FY2014
TTM 9/30/15
Customer/facility count
Payor Neworks under Contract
Growth in Oncology Customers and
Payor
Networks under Contract
*As of September 30, 2015
% of Continuing Customers
Lost Customers
98.7%
1.3%


Value-Creation Takeaway
13
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
STRATEGIC ACQUISITIONS TO
STRENGTHEN MARKET SHARE IN
CORE ONCOLOGY BUSINESS


Strategic Acquisition to Increase Market Share
14
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem
has the largest inventory of home
infusion pumps for the oncology market in the U.S.
In
April
2015,
the
company
acquired
Ciscura
Holding
Company, Inc., based in Alpharetta, Georgia
Acquired inventory of approximately 1,800
infusion pumps
Expand
market
share
with
additional
106 new
infusion clinics relationships for Infusystem
primarily throughout the Southeast
Offer InfuConnect
(EMR) solutions and product
portfolio: pole mounted infusion pumps and
disposables, catheter care kits and chemo safety
products (USP 800)
Open new Southeast Service Center
Enables same day service for equipment and
supplies to much of the Southeast region
“The right pump, the right place, and the right
time.  Working and patient ready.”


Kansas City
Service Center
Madison Heights
Service Center
Future Northeast
Service Center
(est. 2016)
Atlanta
Service Center
(2015)
Los Angeles Area
Service Center
Houston
Service Center
(2014)
Toronto Canada
Service Center
Faster Turnaround Times and Improved Utilization
15
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem
Service Centers
Reduced cost of air shipments
Improved utilization of pump fleet
Increased market share of
“Same-Day” rental market
ISO 9001 Certification and CHAP
accredited quality
Annual pump recertification
Maintenance & Warranty
Ability to service smart pumps
Hub and Spoke Model


Value-Creation Takeaway
16
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
EXPANDING INTO ADJACENT
ADDRESSABLE MARKETS TO
DRIVE GROWTH


17
INNOVATION
|
TEAMWORK
|
INTEGRITY
|
FOCUS
|
PEOPLE
FIRST
Pain
relieving
effects
of
a
peripheral
nerve
block can be extended by using a continuous
peripheral
nerve
block
catheter,
local
anesthetic & an electronic infusion pump
Growing
therapy
in
an
estimated
$700
million market
5.7 million orthopedic surgeries annually
50% are projected to be Continuous
Peripheral Nerve Block Candidates
Pain
most
common
reason
Americans
access
the health care system
Leading cause of disability
Major
contributor
to
health
care
costs.
Per
National
Center
for
Health
Statistics
(2006), approximately
76.2
million,
1
in
every
4 Americans
suffered
from
pain
that
last
longer
than
24
hours
Expansion into At-Home Pain Management
Infusion Pump Market


Value-Creation Takeaway
18
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
INVESTMENTS INTO NEXT GENERATION
SYSTEMS AND TECHNOLOGIES TO
INCREASE CUSTOMER RETENTION


InfuConnect: Enhancing Customer Retention and
Future Growth Driver (EMR)
19
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
EMR Integration –
Simple as 1-2-3
Industry-Leading True-
Paperless Solution
More accurate / More efficient
Smart Data Listener & Extractor
Save up to 20 minutes per patient
Clinics can do more with the time they
have
Ambulatory Infusion Made Easy
On Any Device, Auto loaded
Fastest Implementation
Manage Patients
Monitor Inventory
Sign Orders
Order Supplies
Patient Education and more…


InfuConnect: Life Cycle Management
20
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
State of the Art Asset
Tracking and Management
Track Assets in Real Time
Improve Recovery Rates
Extend Asset Life
Track From Any Device
Fleet Management Made Easy
Order Additional Pumps
Schedule Service & Repair
Access Recertification Docs
Online, Anytime


Pain Management and Reporting
21
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Real-Time Pain Score Reporting
Supporting High Patient Satisfaction
Online, Anytime


Value-Creation Takeaway
22
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
FINANCIAL OVERVIEW


Total Revenue: Total vs Net Collected
23
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
$35.0
$42.7
$50.5
$53.5
$55.8
$60.7
$64.0
$4.0
$4.5
$4.1
$5.3
$6.5
$5.8
$4.8
$39.0
$47.2
$54.6
$58.8
$62.3
$66.5
$68.8
$20
$30
$40
$50
$60
$70
FY2009
FY2010
FY2011
FY2012
FY2013
FY2014
TTM as of 9/30/2015
Net Collected  Revenue
Bad Debt
Total Revenues
(Gross to Net Collected)


Strong Gross and Adjusted EBITDA Margins
24
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Gross Margins
*2014 does NOT add-back the following charges: G&A expense on IT
and Pain Management initiatives of $0.7M, a write-off of pumps
$0.4M, severance of $0.2M
64.7%
72.9%
70.1%
71.2%
70.9%
60%
65%
70%
75%
FY2011
FY2012
FY2013
FY2014
TTM as of
9/30/15
18.8%
22.3%
25.6%
24.2%
25.3%
15%
20%
25%
30%
FY2011
FY2012
FY2013
FY2014*
TTM as of
9/30/15
Adjusted EBITDA Margins
See
Appendix
for
Reg
G
Reconciliation


Free Cash Flow and Adjusted EBITDA
25
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
$0.6
$8.9
$8.5
$0
$1
$2
$3
$4
$5
$6
$7
$8
$9
$10
FY2011
FY2012
FY2013
FY2014
Free Cash Flow*
See
Appendix
for
Reg
G
Reconciliation
$10.3
$13.1
$16.0
$16.1
$17.4
$8
$9
$10
$11
$12
$13
$14
$15
$16
$17
$18
FY2011
FY2012
FY2013
FY2014*
TTM as of
9/30/15
Adjusted EBITDA
See
Appendix
for
Reg
G
Reconciliation
*Free Cash Flow = “Adjusted EBITDA” less “Replacement Cost of Retired
Pumps” less “Scheduled Debt Payments of Principal” less “Interest on Debt”
*2014 does NOT add-back the following charges: G&A expense on IT
and Pain Management initiatives of $0.7M, a write-off of pumps
$0.4M, severance of $0.2M


Net Income and Diluted EPS
26
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
($0.04)
($0.04)
$0.00
$0.01
$0.00
$0.00
$0.03
$0.04
$0.03
$0.04
$0.04
$0.05
$0.03
$0.05
$0.06
($0.06)
($0.04)
($0.02)
$0.00
$0.02
$0.04
$0.06
$0.08
Net Income
($1.5)
$1.7
$3.4
$4.2
($6)
($4)
($2)
$0
$2
$4
$6
FY2011
FY2012
FY2013
FY2014
TTM as of
9/30/15*
Earnings Per Share
Fully Diluted Basis
($45)
($45.4)
*Q1, Q2, & Q3 2015 = Normalized EPS-see Appendix
for Reg
G Reconciliation
*TTM as of 9/30/15 = Normalized Net Income -
see Appendix for Reg
G Reconciliation


Increased Borrowing Facility to Expand Future
Pump Inventory
27
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
$31.0
$34.2
$37.2
$43.1
$45.8
$47.2
$50.0
$25
$30
$35
$40
$45
$50
$55
$5.7
$6.6
$6.4
$7.0
$11.9
$10.7
$10.9
$0
$2
$4
$6
$8
$10
$12
$14
History of strong Free Cash Flows providing added borrowing capacity to expand growth of
pump inventory
Reduced cost of capital on new credit facility allows for increased Return on Invested Capital
Current rate of less than 3.0% vs 18% in 2012, 9.5% in 2013, 7.75% in 2014
New facility signed with Chase in March 2015
Unrestricted Liquidity*
Medical Equipment in
Service (at cost)
$29.1
$31.3
$26.7
$25.5
$33.6
$34.8
$35.2
$15
$20
$25
$30
$35
$40
Total Debt
*Cash and Equivalents + Undrawn Revolver


New $45 Million Credit Facility
28
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
$45 million credit facility signed with JPMorgan Chase in March 2015
Term is five years
$10
million
revolver
undrawn
at
close
$27
million
Term
Loan
A
fully
drawn
at
close
$8
million
Term
Loan
B
undrawn
at
close
Expansion capital (including acquisition of Ciscura)
InfuSystem
has borrowed on this loan to fund the acquisition
of Ciscura
and associated integration costs
Interest rate drops from 7.75% to 3.0%
$1 million in cash interest savings potential
Interest expense in Q3 2015 of $338k down from Q3 2014
of $752k and YTD 2015 interest expense of $1.4m down from
YTD 2014 of $2.4m
Repayment
Term Loan A is repaid $965K quarterly
Term Loan B is repaid quarterly as a percent of the drawn ranging from
3.75% to 4.475%
Favorable covenants and terms
Leverage ratio maximum increased from 2.0x to 3.0x (decreases over
the term)
Fixed charge ratio minimum decreased from 1.75x to 1.25x


Significant Barriers to Entry
29
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Established, long standing relationship with oncology
practices
~1,700 Customer/Facility count*
Growing
Third
Party
Payor
contracts
~340 Payor
networks under contract*
98.7% retention of customer business
Large
fleet
of
ambulatory
infusion
pumps
~60,000
pumps
Generate
revenue
-
Rental
or
sale
Quicker
response
time
-
24/7
Replacement
value
~
$90
million
Geographic coverage U.S. and Canada
5
Regional
Service
Centers
ISO
9001
Same day or next day delivery of pumps
Pump repair and service capabilities
Economies of Scale
EMR Connectivity
Predictable reimbursements
Purchasing power
Management of pump fleet
National presence with Affordable Care Organizations (ACOs)
Physicians, Outpatient oncology practices, hospitals, outpatient surgery centers,
homecare practices, patient rehabilitation centers
*As of September 30, 2015


Why Invest in InfuSystem?
30
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Leading
Operator
in
Core
Business
Oncology
Infusion
Dominate player in oncology infusion market
Large fleet of ambulatory pumps for Rental or Sale
Expanding Market Share
Aging Population and Cancer Growth
Solid Financial Performance
Strong Cash Flows and Solid Gross Margin Profile
Solid Growth in Net Collected Rental Revenue
Improving Net Income
Significantly Reduced Cost of Capital
2015
Guidance
-
Double
Digit
Growth
in
Net
Collected Revenue
Growth
Drivers
-
Pain
Management
and
InfuConnect
(EMR)
Solutions
Peripheral Nerve Block and Smart Pump Growth
True paperless: improved work flow and billing efficiencies
New Management with Highly Focused Initiatives to Drive Value
Increase EMR connectivity “InfuConnect” / Expand into new markets / Reduced cost of capital /
Expand into new therapies, products and services
Gregg O. Lehman, Ph.D. Appointed Chairman of the Board
Elected by the board of directors in May 2015


Questions?
(NYSE MKT: INFU)
IR Contact Info:
Joe Dorame, Managing Partner
Lytham
Partners, LLC
602-889-9700
dorame@lythampartners.com


InfuSystem—Infusion Made Easy
32
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
APPENDIX


Company Snapshot
33
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem
Holdings, Inc.
InfuSystem
Holdings, Inc.
Summary Trading Statistics*
Summary Trading Statistics*
Commentary
Commentary
Financial
Summary ($ in millions)
Financial
Summary ($ in millions)
Headquarters: Madison Heights, MI
Founded: 1998
Specialization: Healthcare / Medical Instruments & Supplies
Management: Eric Steen, President & CEO / Jon Foster, CFO /
Jan Skonieczny, COO / Mike McReynolds, CIO / Sean Schembri,
EVP GC
Est. Number of Employees: 200
LTM Revenue: $68.8M
LTM AEBITDA: $17.4M
*EV / LTM AEBITDA: 5.69x
Stock Price: $2.88
52-Wk Range: $2.22-$3.42
Market Cap: $64.8M
Enterprise Value: $99.1M
EV / LTM AEBITDA: 5.69x
P / LTM Adj. Earnings:  15.1x
InfuSystem
provides infusion pumps and related products
and services for patients in:
Patient’s home,
Oncology clinics
Ambulatory surgery centers
Other health care sites
6 Regional Service Centers serves all of North America
Profitable growth
Oncology and orthopedic surgery
Increased electronic connectivity
New products and services
Strategic geographic expansion
*As of 1/26/16
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
$0.00
$1.00
$2.00
$3.00
$4.00
$5.00
1/13
4/13
7/13
10/13
1/14
4/14
7/14
10/14
1/15
4/15
7/15
10/15
Share Price
Volume
$39.0
$47.2
$54.6
$58.8
$62.3
$66.5
$68.8
19%
22%
26%
24%
25%
0%
5%
10%
15%
20%
25%
30%
$0
$10
$20
$30
$40
$50
$60
$70
$80
FY2009
FY2010
FY2011
FY2012
FY2013
FY2014
TTM
9/30/15
1/16


InfuSystem
Niche –
Extension of Clinic to Home
34
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Ambulatory Home Infusion
Ambulatory Home Infusion
25-year old business model in
DME billing
At home, at work, at play, all while
receiving the drug
High satisfaction scores
24/7 on-call oncology nurses
Proven outcomes with continuous
home infusion
Oncology, Post Surgical Pain,
Special Disease States
Patient-Based
Rental
TPP
Payor
Contracts
Patient-Based
Rental
TPP
Payor
Contracts
Bills patient insurance
300+ Payor
Networks
under Contract
(Commercial and
Government)
Commercial Payors
reimburse more
therapies than CMS
Awarded contracts in
all 9
MSAs (1 of 4
National Vendors)
Average Round 1
Recompete
cuts of
~21% for our category,
per CMS ($250,000 per
yr
beginning in
January 2014, see CMS
Competitive Bidding
Summary slide in
Appendix)


Hospital-Home Care Based Direct Payor
Business Model
35
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Infusion pumps
Enteral pumps
InfuSystem’s
Hospital-Home Care Based (DP) business is focused primarily on the sale, rental, financing and
accompanying service of movable medical equipment to hospitals and alternate care sites who pay InfuSystem
directly –
no third-party reimbursement
Founded in 1998 and currently headquartered in Lenexa, KS
InfuSystem
services –
ISO 9001 -
and repairs movable medical equipment
Leading provider to alternate site healthcare facilities and hospitals in the United States and Canada
Home infusion providers, long-term care, physician clinics, research facilities, etc.
Transacts
directly
with
healthcare
providers
no
third-party
reimbursement
revenue
Service & Repair
Products
InfuSystem sells, rents and finances a wide variety of new
and used large volume and ambulatory pumps
InfuSystem services and repairs both its own fleet of
pumps and many types of other movable medical
equipment
Syringe pumps
Ambulatory pumps
Large volume pumps
Ambulatory pumps
Fluid collection
Medical equipment


Hospital-Home
Care
Based
Direct
Payor
Offerings
36
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem offers new pumps from top brands
Broker-dealer trading desk
In addition, over 70 models and versions of pre-owned
pumps are offered
Pre-owned pumps are re-built and certified by in-house
biomedical technicians to be patient ready
Warranty offered on pre-owned pumps
A variety of financing options to fit customers’ operating,
budgeting and financing parameters
Nationwide, industry-leading ISO 9001 service programs
Launching 7
th
location -
Northeast service center
Pre-Owned & New Pumps from Top Manufacturers
Pre-Owned & New Pumps from Top Manufacturers
Full Spectrum of Ownership Options for Customers
Full Spectrum of Ownership Options for Customers
Sales
Sales
Rental
Rental
Asset Management
Asset Management
Renting new or pre-owned equipment
Rent pumps by the day, week or month
to match swings in patient count
Free shipping on all rentals
Industry leader in sales of pre-owned
equipment, creating significant savings
Competitive pricing on new equipment
Option to sell back pre-owned pumps
Leasing plans offered
ISO 9001 Service offered
Service plans offered
Local service expansion
6 existing; 1 planned
Coordinate with Patient-Based
Loaner pumps available
Leading Provider of New and Pre-Owned Pumps
Leading Provider of New and Pre-Owned Pumps


Medical Equipment Service & Repair
37
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
In addition to supporting and repairing InfuSystem’s
in-house fleet, the Company certifies, recalibrates,
repairs and services a variety of infusion pumps
Pumps require scheduled maintenance and
calibration in accordance with manufacturer’s
specifications and regulatory guidelines
Service and repair capabilities on high demand
services reaching end of life that are no longer
supported by manufacturers
ISO certification and an established quality system
strengthens relationships with major customers
Provides InfuSystem
an opportunity to establish a
business relationship with customers that acquired
pumps through other sources
Continuing and increased need for compliance with
current as well as anticipated regulations
28 highly qualified service technicians
5 major manufacturer relationships:
6 service centers, located in Michigan,
Kansas, California, Texas, Georgia and
Toronto, Canada


Competitive Bidding Overview
38
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
InfuSystem
was not involved in Round 1 nor Round 2 of
Competitive Bidding
CMS completed a Recompete of Round 1 competitive
bidding in late 2013 which covered 9 Metropolitan
Statistical Areas (MSAs) and with the results taking effect
January 1, 2014
CMS published a Final Rule in the Federal Register on
November 6, 2014 that describes the methodology for
reimbursement cuts for items/services provided to
patients outside of MSAs subject to competitive bidding
The Company estimates this Rule will impact
revenues by $2-3 million annually beginning in
2016
Competitive Bidding Overview
InfuSystem’s
Response to Competitive Bidding
InfuSystem has actively prepared the Company for potential
regulatory changes and reimbursement changes
During
the
2013
Round
1
Recompete,
InfuSystem
was
awarded
contracts in ALL of the 9 MSAs with average cuts of ~21% for
our category (per CMS).
1 of only 4 National Vendors to receive contracts in all
9 markets in our category
InfuSystem
has pursued contract negotiations with commercial
payors
and has been successful in receiving positive rate
adjustments which will help offset any CMS cuts
“Competitive environment will vary in accordance with the
level of cuts by CMS”
CMS Competitive Bidding Timetable
CMS began the
pre-bidding
supplier
awareness
program
CMS
announced
bidding
schedule, start
bidder
education and
begin a bidder
registration
period
Bid window
opens
Current Round
1 bid contracts
expire
CMS
announces
Round 1
Recompete
bid
results –
INFU
impact $250K
annually
Bid window
closes
Implementation
of Round 1 bid
contracts and
prices
Spring
2012
08/16/12
10/15/12
12/14/12
10/1/13
12/31/13
01/01/14
11/06/14
04/21/15
FY2016
12/31/16
CMS announces
bidding schedule
for next bidding
round–
External
Infusion pumps
EXCLUDED
CMS published
the Final Rule in
the Federal
Register –
INFU
impact $2-3
million annually
beginning 2016
Final Rule cuts
begin to take
effect
Contracts from
Round 1
Recompete
expire


t
Impact of Debt & Leverage on Valuation Multiple
39
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
73.0%
76.0%
44.0%
53.0%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
3X
4X
5X
6X
7X
8X
9X
10X
Enterprise Value / AEBITDA
Q1-13
Stock Price = $1.69
EV = $66.1M
AEBITDA = $15.0M
Q1-14
Stock Price = $2.77
EV = $89.5M
AEBITDA = $15.6M
Q2-15
Stock Price = $2.88
EV = $100.3M
AEBITDA = $16.5
Q1-12
Stock Price = $1.96
EV = $71.5M
AEBITDA = 14.0M
Management’s strategy is to increase
enterprise value (EV) and lower
leverage via a combination of profitable
growth and repayment of debt
Management believes high historic
leverage have depressed INFU valuation
multiples due to market-perceived risk
of debt overhang
Favorable reaction to increase in
AEBITDA and decreasing leverage can
already be seen by movement along
trend line
Note that Q2-15 shows full debt impact
of Ciscura
acquisition but only one+
month of contribution.
Source: Stock price -
Yahoo on closest date to quarter close.  AEBITDA is TTM.
Size of bubble represents EV


40
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
April 2015 -
Acquires Ciscura
for $5.4M
Leverage: Total Debt to Book Equity
US$ millions
$29.13
$31.27
$26.73
$25.48
$35.24
$0.80
$2.33
$1.14
$0.52
$0.99
73%
78%
63%
55%
72%
0%
15%
30%
45%
60%
75%
90%
$0
$10
$20
$30
$40
$50
2011
2012
2013
2014
9 Months Ended
09/30/15
Total Debt
Cash
Debt to Equity Ratio
Fiscal Year


Non-GAAP Reconciliation:
Annual Net Income to Adjusted EBITDA
41
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Unaudited, in US$ thousands
FY2011
FY2012
FY2013
FY2014
plus Interest
2,193
3,340
3,497
3,134
plus Tax
(23,134)
(663)
1,031
2,853
plus Depreciation
6,386
5,668
5,415
3,626
plus Amortization
2,662
2,734
2,618
2,516
EBITDA
(57,336)
9,590
14,230
15,485
plus Impairment Charges
67,592
-
plus Loss (Gain) on Derivatives
-
plus Concerned Shareholders
2,220
-
plus Extinguishment of Debt
671
-
plus Stock Based Compensation
1,120
576
plus Strategic Alternatives & Transition
645
604
-
Net Income
(45,443)
(1,489)
1,669
3,356
Adjusted EBITDA
10,256
13,126
15,954
16,061


Non-GAAP Reconciliation:
TTM Net Income to Adjusted EBITDA by Quarter
42
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Unaudited, in US$ thousands
4Q
2014
1Q
2015
2Q
2015
3Q
2015
Trailing 12
Months
Net Income
1,369
2,773
plus Interest Expense
779
672
387
338           
2,176
plus Income Tax Expense
946
(285)
147
957
1,765
plus Depreciation
1,031
1,103
1,229
1,414
4,777
plus Amortization
640
631
713
756
2,740
EBITDA
4,432
1,706
3,259
4,834
14,231
plus Impairment Charges
plus Loss (Gain) on Derivatives
plus Concerned Shareholders
plus Extinguishment of Debt
1,599
-
-
1,599
plus Stock Based Compensation
159
287
330
179
955
plus Strategic Alternatives & Transition
255
351
22
628
Adjusted EBITDA
4,591
3,847
3,940
5,035
17,413
1,036
(415)
783


Non-GAAP Reconciliation:
Annual Net Income to Free Cash Flow*
43
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
*It is important to note that in looking at our cash flow statement that replacement pump purchases are often done in large
lots which result in wide variances in free cash flow quarter to quarter. For this reason, we focus on annual free cash flow.
** Management estimate based on pumps retired and an assumed average replacement cost per period.
Unaudited, in US$ thousands
FY2011
FY2012
FY2013
FY2014
Net Income
(45,443)
(1,489)
1,669
3,356
plus Interest
2,193
3,340
3,497
3,134
plus Tax
(23,134)
(663)
1,031
2,853
plus Depreciation
6,386
5,668
5,415
3,626
plus Amortization
2,662
2,734
2,618
2,516
EBITDA
(57,336)
9,590
14,230
15,485
plus Impairment Charges
67,592
-
plus Loss (Gain) on Derivatives
-
plus Concerned Shareholders
2,220
-
plus Extinguishment of Debt
671
-
plus Stock Based Compensation
1,120
576
plus Strategic Alternatives & Transition
645
604
-
Adjusted EBITDA
10,256
13,126
15,954
16,061
less Replacement Cost of Retired Pumps**
(1,803)
(512)
(447)
(1,055)
less Scheduled Debt Payments of Principal
(5,953)
(9,631)
(3,771)
(3,860)
less Interest on Debt
(1,934)
(3,112)
(2,881)
(2,662)
Free Cash Flow
566
(129)
8,855
8,484


Non-GAAP Reconciliation: TTM Operating Income to
Normalized Net Income and EPS by Quarter
44
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
Unaudited, in US$ thousands except per share values
4Q
2014
1Q
2015
2Q
2015
3Q
2015
Trailing 12
Months
Operating Income
$2,774
$1,552
$1,317
$2,711
$8,354
Adjustments:
Integration
Costs
Ciscura
0
255
351
22
628
Interest Expense
(779)
(672)
(387)
(338)
(2,176)
Other income
(13)
(19)
0
(47)
(79)
Income
before
income
taxes
adjusted
$1,982
$1,116
$1,281
$2,348
$6,727
Other income
946
454
205
963
2,568
NORMALIZED
NET INCOME
$1,036
$662
$1,076
$1,385
$4,159
Normalized
Net income
per share:
Basic
$0.05
$0.03
$0.05
$0.06
$0.19
Diluted
$0.05
$0.03
$0.05
$0.06
$0.19
Weighted average shares outstanding:
Basic
22,291
22,309
22,381
22,449
22,358
Diluted
22,825
22,309
22,825
22,838
22,699


Detailed Historical P&L
45
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST
(000's)
12/31/09
12/31/10
12/31/11
12/31/12
12/31/13
12/31/14
Net revenues:
Rentals
38,606
$        
43,384
$        
46,795
$        
53,471
$        
55,962
$        
58,718
$        
Product sales
358
               
3,845
           
7,842
           
5,357
           
6,318
           
7,769
           
Net revenues:
38,964
         
47,229
         
54,637
         
58,828
         
62,280
         
66,487
         
Cost of Revenues:
Product, service and supply costs
6,200
           
7,730
           
9,128
           
9,165
           
11,274
         
12,165
         
Pump depreciation and loss on disposal
4,127
           
5,954
           
10,154
         
6,752
           
7,327
           
6,968
           
Gross Profit
28,637
         
33,545
         
35,355
         
42,911
         
43,679
         
47,354
         
Provision for doubtful accounts
4,006
           
4,515
           
4,099
           
5,251
           
6,534
           
5,774
           
Amortization of intangibles
1,827
           
2,259
           
2,662
           
2,734
           
2,618
           
2,516
           
Asset impairment charges
0
                   
0
                   
67,592
         
0
                   
0
                   
0
                   
Selling and marketing
5,258
           
7,087
           
9,371
           
9,864
           
9,658
           
9,745
           
General and administrative
12,218
         
20,622
         
17,987
         
23,062
         
18,973
         
19,988
         
Operating income profit/(loss)
5,328
           
(938)
             
(66,356)
       
2,000
           
5,896
           
9,331
           
Total other gain/(loss)
(3,577)
          
(2,285)
          
(2,221)
          
(4,152)
          
(3,196)
          
(3,121)
          
Profit/(loss) before income taxes
1,751
           
(3,223)
          
(68,577)
       
(2,152)
          
2,700
           
6,210
           
Income tax benefit/(expense)
(977)
             
1,371
           
23,134
         
663
               
(1,031)
          
(2,853)
          
Net income/(loss)
774
$              
(1,852)
$         
(45,443)
$       
(1,489)
$         
1,669
$          
3,357
$          
EBITDA
11,199
$        
7,745
$          
(57,336)
$       
9,590
$          
14,230
$        
15,486
$        
EBITDA (ex. Impairment charges)
11,199
$        
7,745
$          
10,256
$        
9,590
$          
14,230
$        
15,486
$        
Adjusted EBITDA
N/A
               
N/A
               
10,256
$        
13,126
$        
15,954
$        
16,062
$        


Detailed Historical Balance Sheet
46
INNOVATION  |  TEAMWORK  |   INTEGRITY  |  FOCUS  |  PEOPLE FIRST